Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

72.15
-2.0900-2.82%
Post-market: 72.150.00000.00%17:50 EDT
Volume:1.95M
Turnover:141.16M
Market Cap:11.92B
PE:-30.32
High:74.05
Open:74.00
Low:71.87
Close:74.24
52wk High:86.74
52wk Low:23.95
Shares:165.19M
Float Shares:164.00M
Volume Ratio:0.70
T/O Rate:1.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3800
EPS(LYR):-2.3812
ROE:-70.80%
ROA:-7.31%
PB:24.37
PE(LYR):-30.30

Loading ...

Ionis Receives U.S. FDA Breakthrough Therapy Designation for Olezarsen for Severe Hypertriglyceridemia (Shtg)

THOMSON REUTERS
·
Dec 01, 2025

Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference

GlobeNewswire
·
Dec 01, 2025

Why Ionis Pharmaceuticals (IONS) Is Up 8.7% After Donidalorsen EMA Milestone and $700 Million Offering News

Simply Wall St.
·
Nov 30, 2025

Ionis Pharmaceuticals EVP Chief Human Resources Officer Shannon L. Devers Reports Sale of Common Shares

Reuters
·
Nov 29, 2025

Ionis Pharmaceuticals Director Joseph Klein III Reports Disposal of Common Shares

Reuters
·
Nov 29, 2025

Director’s Multi-Million Dollar Stock Sale Shakes Ionis Pharmaceuticals

TIPRANKS
·
Nov 21, 2025

Ionis Pharmaceuticals Director Joan E. Herman Reports Sale of Common Shares

Reuters
·
Nov 21, 2025

Ionis Announces Proposed Convertible Offering To Refinance 2026 Convertible Notes

Reuters
·
Nov 20, 2025

Arrowhead Pharmaceuticals Poised for Commercial Transition After First FDA Approval, RBC Says

MT Newswires Live
·
Nov 20, 2025

Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein

TIPRANKS
·
Nov 19, 2025

US FDA approves Arrowhead's genetic disorder drug

Reuters
·
Nov 19, 2025

Ionis Pharmaceuticals Completes $770M Convertible Notes Offering

TIPRANKS
·
Nov 18, 2025

Ionis Pharmaceuticals Announces $700 Million Convertible Senior Notes Offering

Reuters
·
Nov 18, 2025

Biogen Gets CHMP Backing for Higher-Dose Spinraza

Dow Jones
·
Nov 17, 2025

Ionis Pharmaceuticals announces CHMP opinion recommending Dawnzera approval

TIPRANKS
·
Nov 14, 2025

Ionis Pharmaceuticals Says Dawnzera Recommended for Approval in EU for Hereditary Angioedema

MT Newswires Live
·
Nov 14, 2025

Ionis Pharmaceuticals Wins CHMP Backing for DAWNZERA in Hereditary Angioedema Prevention

Reuters
·
Nov 14, 2025

Ionis Pharmaceuticals Inc - European Commission Decision Expected in Q1 2026

THOMSON REUTERS
·
Nov 14, 2025

Dawnzera™ (Donidalorsen) Receives Positive Opinion From Chmp, Recommended for Approval in EU for Hereditary Angioedema (Hae)

THOMSON REUTERS
·
Nov 14, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Broadwind, Verizon, APA

Reuters
·
Nov 14, 2025